Redefining vaccine trial recruitment
Redefining Vaccine Trial Recruitment
Key Challenges
- Low participation rates - Less than 4% of the U.S. population participates in clinical trials6
- High dropout rates - Only 7% of participants complete studies6
- Compressed timelines and urgency, especially during pandemics1
- Public trust issues and vaccine hesitancy13
- Accessibility barriers for diverse populations1
- Retention difficulties for long-term trials1
Innovative Strategies
- Digital recruitment platforms for broader, targeted outreach1
- Community-based recruitment to build trust and cultural sensitivity14
- Decentralized trials with remote monitoring to improve accessibility1
- AI and large language models to enhance patient matching and data analysis6
- Blockchain technology to ensure data integrity and security6
- Tailoring recruitment approaches to specific communities and regions5
Key Facts
- 85% of clinical trials experience delays6
- Each day of delay costs pharma companies $600,000 to $8 million6
- The global vaccine market exceeded $76 billion in 20231
- mRNA vaccines captured 32% market share in 2023-241
Best Practices
- Engage communities early and throughout the trial process4
- Use multi-step consent processes to adequately educate participants4
- Employ diverse recruitment strategies tailored to each region5
- Leverage technology while maintaining ethical standards and patient privacy6
- Focus on building long-term trust and relationships with communities14
Redefining vaccine trial recruitment requires balancing technological innovation with community engagement, cultural sensitivity, and ethical considerations to improve efficiency, diversity, and overall trial quality.
Sources:
1. https://allianceclinicalnetwork.com/overcoming-recruitment-challenges-in-the-current-vaccine-boom/
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8751669/
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4185896/
5. https://www.fredhutch.org/en/news/spotlight/2020/10/broderviddplosone.html
6. https://acrpnet.org/2024/06/13/disruptive-technologies-redefining-the-path-of-clinical-trials